147 related articles for article (PubMed ID: 2148744)
1. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
Invest New Drugs; 1990 Aug; 8(3):317-9. PubMed ID: 2148744
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of the synthetic retinoid Fenretinide (HPR).
Costa A; Malone W; Perloff M; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M; Andreoli C; Del Vecchio M
Eur J Cancer Clin Oncol; 1989 May; 25(5):805-8. PubMed ID: 2525470
[TBL] [Abstract][Full Text] [Related]
3. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
4. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of breast cancer with retinoids.
Veronesi U; De Palo G; Costa A; Formelli F; Marubini E; Del Vecchio M
J Natl Cancer Inst Monogr; 1992; (12):93-7. PubMed ID: 1535505
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
8. Distribution of fenretinide in the mammary gland of breast cancer patients.
Mehta RG; Moon RC; Hawthorne M; Formelli F; Costa A
Eur J Cancer; 1991; 27(2):138-41. PubMed ID: 1827276
[TBL] [Abstract][Full Text] [Related]
9. Subacute toxicity of all-trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide.
Sani BP; Meeks RG
Toxicol Appl Pharmacol; 1983 Sep; 70(2):228-35. PubMed ID: 6226123
[TBL] [Abstract][Full Text] [Related]
10. Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide.
Paulson JD; Oldham JW; Preston RF; Newman D
Fundam Appl Toxicol; 1985 Feb; 5(1):144-50. PubMed ID: 3157610
[TBL] [Abstract][Full Text] [Related]
11. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide.
Formelli F; Barua AB; Olson JA
FASEB J; 1996 Jul; 10(9):1014-24. PubMed ID: 8801162
[TBL] [Abstract][Full Text] [Related]
12. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells.
Mehta RR; Hawthorne ME; Graves JM; Mehta RG
Eur J Cancer; 1998 May; 34(6):902-7. PubMed ID: 9797705
[TBL] [Abstract][Full Text] [Related]
14. Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide.
Filiberti A; Tamburini M; Andreoli C; Buranelli F; Campa T; Costa A; Dossena G; Magni A; Pizzichetta M; Ventafridda V
Tumori; 1988 Jun; 74(3):353-6. PubMed ID: 2969638
[TBL] [Abstract][Full Text] [Related]
15. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
[TBL] [Abstract][Full Text] [Related]
16. Retinoids, breast cancer and NK cells.
Villa ML; Ferrario E; Trabattoni D; Formelli F; De Palo G; Magni A; Veronesi U; Clerici E
Br J Cancer; 1993 Nov; 68(5):845-50. PubMed ID: 8217599
[TBL] [Abstract][Full Text] [Related]
17. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer.
Cobleigh MA; Dowlatshahi K; Deutsch TA; Mehta RG; Moon RC; Minn F; Benson AB; Rademaker AW; Ashenhurst JB; Wade JL
J Clin Oncol; 1993 Mar; 11(3):474-7. PubMed ID: 8445423
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of fenretinide [N-(4-hydroxyphenyl) retinamide] in myelodysplasia: possible retinoid-induced disease acceleration.
Garewal HS; List A; Meyskens F; Buzaid A; Greenberg B; Katakkar S
Leuk Res; 1989; 13(4):339-43. PubMed ID: 2523991
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between plasmatic levels of retinol and RBP and thyroid hormones in breast cancer patients treated with the synthetic retinoid fenretinide.
Pizzichetta M; Formelli F; Bombardieri E; Bruni GF; Costa A
Int J Biol Markers; 1990; 5(4):208. PubMed ID: 2151235
[No Abstract] [Full Text] [Related]
[Next] [New Search]
